When the primary signaling pathways in tumor cells are inhibited by TKI drugs, the tumor cells can reactivate key downstream effectors required for cell survival and proliferation through parallel signaling pathways of other receptor tyrosine kinases (RTKs). This evidence concerns the gene NTRK1 and neoplasm.